Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders - PubMed
4 hours ago
- #CNS disorders
- #nanoparticles
- #drug delivery
- Nanoparticles (NPs) enable tunable delivery across the blood-brain barrier (BBB) and targeted therapy for central nervous system (CNS) disorders.
- NPs are applied in drug delivery, imaging, gene therapy, and neuroprotection for conditions like Alzheimer's, Parkinson's, depression, and schizophrenia.
- Current clinical translation is limited but includes trials of gold-based agents, intranasal formulations, and liposomal modulators.
- Challenges include BBB variability, immunogenicity, production stability, and limited human exposure-response data.
- Future directions involve model-informed development, Quality-by-Design manufacturing, adaptive trials, and targeting the gut-brain axis.